PCVX
Vaxcyte, Inc.
October 9, 2026 · market open
- Rarity
- 1.89
- Peak move
- +11.37%
- Float cap
- $8.3B
Vaxcyte, Inc. is a clinical-stage vaccine innovation company that engineers high-fidelity vaccines against bacterial diseases. It uses its XpressCF cell-free protein synthesis platform to develop conjugate and protein vaccine candidates for adult and pediatric indications. Its pipeline includes broad-spectrum pneumococcal conjugate vaccine candidates designed to prevent invasive pneumococcal disease, pneumonia, and related infections.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 1 from SEC or newswire · 0 timed with the moveanalyst_ratingA FactSet survey of 9 analysts raised the median price target on Vaxcyte to $122 from $105.50, a 15.64% increase, with a high estimate of $163 and a low of $75.
equity_offeringVaxcyte priced and closed concurrent offerings of 7,412,500 common shares at $64.00, pre-funded warrants for 400,000 shares at $63.999, and $575 million of 1.50% convertible senior notes due 2032, raising roughly $1.15 billion gross including full exercise of the over-allotment option, with the common stock and pre-funded warrant offering priced at a discount to the prior close of $66.70.
shelf_registrationVaxcyte's concurrent common stock, pre-funded warrant and convertible note offerings were made off an automatically effective shelf registration statement filed with the SEC and effective May 24, 2024, with preliminary and final prospectus supplements filed.
analyst_ratingJefferies maintained a Buy rating on Vaxcyte with a $146 price target and Mizuho Securities maintained a Buy rating with a $163 price target following the positive VAX-31 OPUS-1 Phase 3 data.
analyst_ratingBank of America Securities raised its price target on Vaxcyte to $146 from $130 while reiterating a Buy rating.
analyst_ratingNeedham raised its price target on Vaxcyte to $122 from $110 while maintaining a Buy rating, following the positive Phase 3 OPUS-1 results for VAX-31.
clinical_readoutVaxcyte reported positive topline data from the pivotal Phase 3 OPUS-1 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, meeting all 32 prespecified co-primary immunogenicity endpoints in adults 50 and older, with noninferiority for shared serotypes versus Pfizer's Prevnar 20 (PCV20) and Merck's Capvaxive (PCV21) and superiority for three VAX-31-unique serotypes plus cross-reactive 20B; a BLA filing is planned for H1 2028, and the company hosted a webcast and conference call with a related slide presentation.